JFS Wealth Advisors’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

JFS Wealth Advisors’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-25	Closed	–	–	569
2017 Q3	$0	Hold	25	–	–	﹤0.01%	466
2017 Q2	$0	Hold	25	–	–	﹤0.01%	473
2017 Q1	$1K	Hold	25	–	–	﹤0.01%	434
2016 Q4	$1K	Hold	25	–	–	﹤0.01%	434
2016 Q3	$1K	Hold	25	–	–	﹤0.01%	474
2016 Q2	$1K	Hold	25	–	–	﹤0.01%	489
2016 Q1	$2K	Hold	25	–	–	﹤0.01%	539
2015 Q4	$2K	Hold	25	–	–	﹤0.01%	511
2015 Q3	$2K	Hold	25	–	–	﹤0.01%	448
2015 Q2	$2K	Hold	25	–	–	﹤0.01%	479
2015 Q1	$2K	Hold	25	–	–	﹤0.01%	474
2014 Q4	$2K	Buy	25 +12	+92%	+$874	﹤0.01%	491
2014 Q3	$1K	Buy	+13	New	+$695	﹤0.01%	474

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JFS Wealth Advisors's MACK Position: Q4 2017 in Review

JFS Wealth Advisors sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2017, closing a stake of 25 shares.

JFS Wealth Advisors first reported a position in MACK in Q3 2014 and held it in 13 quarters. The position peaked at $2K in Q1 2016. 78 funds tracked by Wall St. Rank hold MACK as of Q4 2017.

JFS Wealth Advisors reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
JFS Wealth Advisors sold 25 Merrimack Pharmaceuticals, Inc. shares in Q4 2017.
JFS Wealth Advisors first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2014 and held it in 13 quarters.
JFS Wealth Advisors's Merrimack Pharmaceuticals, Inc. position peaked at $2K in Q1 2016.
78 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2017.

Based on JFS Wealth Advisors's 13F filing for Q4 2017, filed 31 Jan 2018.